Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.81
10.44
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
Income from Continuing Operations
Aurinia Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Income from Continuing Operations
-$22.6m
|
CAGR 3-Years
47%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-4%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Income from Continuing Operations
-CA$7.4m
|
CAGR 3-Years
-149%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Income from Continuing Operations
-$3.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
Income from Continuing Operations
-$28.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-32%
|
|
|
Covalon Technologies Ltd
XTSX:COV
|
Income from Continuing Operations
-CA$823.4k
|
CAGR 3-Years
52%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Income from Continuing Operations
-CA$25.1m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
-9%
|
|
Aurinia Pharmaceuticals Inc
Glance View
In the heart of the pharmaceutical world, Aurinia Pharmaceuticals Inc. has carved out a niche with its focus on tackling autoimmune diseases, primarily targeting lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus. This Canadian company made waves with the development and approval of its flagship product, Lupkynis (voclosporin), an oral medication designed to treat this specific condition. By addressing a critical unmet need for patients grappling with the debilitating effects of lupus nephritis, Aurinia not only provides a precious lifeline for many but also positions itself as a significant player within the rare disease market. The development of Lupkynis was not just a scientific endeavor; it was a strategic move backed by rigorous clinical trials that underscored the efficacy and safety needed to gain regulatory approval and, ultimately, market trust. Aurinia’s revenue stream is primarily generated through the commercialization of Lupkynis, which has proved crucial in building its financial foundation. The company has embraced a commercialization strategy that involves direct sales, supported by partnerships and collaborations that enhance its reach and distribution capabilities. This approach allows Aurinia to maintain a strong connection to the markets it serves, providing valuable insights into emerging patient needs and market trends. Meanwhile, the company’s robust pipeline reflects its commitment to innovation, featuring additional immunology-focused therapies that could, over time, broaden its portfolio and potentially unlock new revenue streams. Integral to Aurinia’s success is its strategic focus on niche areas where the competition may be limited, giving it a distinctive edge in the complex world of pharmaceutical development.
See Also
What is Aurinia Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-22.6m
USD
Based on the financial report for Sep 30, 2024, Aurinia Pharmaceuticals Inc's Income from Continuing Operations amounts to -22.6m USD.
What is Aurinia Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-4%
Over the last year, the Income from Continuing Operations growth was 71%. The average annual Income from Continuing Operations growth rates for Aurinia Pharmaceuticals Inc have been 47% over the past three years , 18% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
